ǰÑÔ
Ö¬·¾¸Î(fatty liver disease,FLD)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔÓÉÒýÆðµÄ¸ÎÔàÖ¬·¾´úлÕϰ£¬Ö¬ÀàÎïÖʵĶ¯Ì¬Æ½ºâʧµ÷£¬¸Îϸ°ûÄÚÖ¬·¾Èº¼¯¹ý¶àµÄ²¡±ä¡£Ö¬·¾¸ÎµÄ·¢²¡ÂʽüÄêÀ´Ñ¸ËÙÉÏÉý£¬ÒѳÉΪ½ö´ÎÓÚ²¡¶¾ÐÔ¸ÎÑ׵ĵڶþ´ó¸Î²¡£¬ÕýÑÏÖØÍþв¹úÈ˵Ŀµ½¡¡£Æ¾Ö¤²¡Òò£¬Ö¬·¾¸Î¿É·ÖΪ·Ç¾Æ¾«ÐԺ;ƾ«ÐÔÁ½´óÀà¡£·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡(nonalcoholic fatty liver disease, NAFLD)·¢²¡»úÖÆÏÖÔÚÉÐδÃ÷È·£¬ÖÎÁÆÉÏҲȱ·¦ÓÐÓò½·¥£¬ÊÇÏÖÔÚÑо¿µÄÖØµã¡£¾Æ¾«ÐÔÖ¬·¾¸Î¶¯ÎïÄ£×ÓÒÔÒûʳÓÕµ¼ÎªÖ÷£¬¾Æ¾«¿Éʹ¶¯Îï¸ÎÔàÑõÏûºÄÂÊÔö¸ß£¬ÔöÌíѪñ¼ÑªµÄÑõÏûºÄ£¬´Ó¶øïÔ̶ÔСҶÖÐÐĸÎϸ°ûµÄÑõ¹©£¬ÒýÆð¸ÃÇøÓòµÄ¸Îϸ°ûÍË»¯Ó뻵ËÀ£¬²¢±¬·¢Ö¬·¾±äÐÔ¡£ÀíÏëµÄÖ¬·¾¸Î¶¯ÎïÄ£×ÓÓ¦ÓëÈËÀàÖ¬·¾ÐԸβ¡µÄÌØÕ÷ÏàËÆ£¬¼´²¡±äÉú³¤Àú³ÌÓÐÏà¶ÔÏÔ×ÅµÄ·ÖÆÚ£¬´Ó´¿´âÐÔÖ¬·¾¸Î¡¢Ö¬·¾ÐÔ¸ÎÑס¢¸ÎÏËά»¯ÖÁ¸ÎÓ²»¯£¬²¢ÇÒÓ¦¾ßÓÐÄ£×ÓÐγÉÂʸߡ¢éæÃüÂʵ͡¢ÔìÄ£ÒªÁìÇáÓ¯Ò×ÐС¢¶ÔʵÑéÖ°Ô±ÎÞº¦¡¢ÔìÄ£×èÖ¹ºó²¡±äÄæ×ª»ºÂý£¬±ãÓÚ¾ÙÐÐÒ©Îï¸ÉÔ¤ÊÔÑéµÈÌØµã¡£ÏÖÔÚÒѾÔÚ´óÊó¡¢É³Êó¡¢Ð¡Êó¡¢¼ÒÍúÍÖíµÈ¶¯ÎïÖÖÊôÀֳɵؽ¨ÉèÁËÖ¬·¾¸Î¶¯ÎïÄ£×Ó£¬ÕâЩ¶¯ÎïÄ£×ÓΪÃ÷È·Ö¬·¾¸Î·¢²¡»úÖÆ¡¢É¸Ñ¡Ò©ÎïµÈ»ù´¡ºÍÁÙ´²Ñо¿ÌṩÁ˺ܺõÄʵÑ鹤¾ß¡£
FLD¶¯ÎïÄ£×ÓÖ÷Òª·ÖΪËÄ´óÀࣺ×Ô¾õÐÔÄ£×Ó£¬»ùÒòÐÞÊζ¯ÎïÄ£×Ó£¬Òûʳ¡¢Ò©Îï»ò¶¾ÎïÓÕµ¼Ä£×Ó£¬¸´ºÏÄ£×Ó£¨ÍŽáÓ¦ÓûùÒòÄ£×ÓºÍÓªÑøÄ£×Ó£©¡£ËüÃÇÔÚ²î±ðµÄ²ãÃæÊ©Õ¹×÷Ó㬵«×îÖÕÖ÷ÒªÊÇͨ¹ýʹ¸ÎÔàÖ¬·¾ÊäÈ루ºÏ³É»òÉãÈ룩ÔöÌí»òÊä³ö£¨É¨³ý£©ïÔ̵ÄÔÀíÖÆ³É¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó¡¢Ð¡Êó
¡¾ÔìÄ£ÒªÁì¡¿£º
µ¨¼îµ°°±Ëáȱ·¦(methioninecholine-deficient,MCD)Òûʳ³£ÓÃÀ´ÓÕµ¼¾µäµÄNAFLD¶¯ÎïÄ£×Ó¡£MCDÒûʳ¸»º¬Ì¼Ë®»¯ºÏÎï(40%)ºÍÖ¬·¾(10%£©£¬µ«È±·¦¼ÓÈë¸Îϸ°ûÖ¬·¾ËáβÑõ»¯ºÍºÏ³É¼«µÍÃܶÈÖ¬ÂѰ׵ĵ°°±ËáºÍµ¨¼î£¬ÓÃÓÚÎ¹ÑøµÄÄö³ÝÀදÎÈç´óÊóºÍСÊó¡£
¸ßÖ¬Òûʳ(high fat diet,HFD)Ä£×Ó£ºÊ¹ÓÃHFD£¨Ì¼Ë®»¯ºÏÎï¡¢Ö¬·¾¡¢ÂѰ×ÖÊ»®·ÖÕ¼×ÜÈÈ×îµÄ52%¡¢30£¥ºÍ18%£©ËÇÑø´óÊó¡¢ëàÊó¡¢¼ÒÍá¢È®µÈ¾ù¿ÉÓÕ·¢NAFLD¡£
ȫ賦ÍâÓªÑø(total parenteral nutrition,TPN)Ä£×Ó£º³ÉÄê´óÊóÉî¾²Âö£¨ÈçÉÏÇ»¾²Âö£©²å¹Ü£¬ÅþÁ¬ÊäÒº±Ã½«·ÇÂѰ×ÓªÑøÒº£¨Èç¸ßÆÏÌÑÌǼӰ±»ùËáµÄ¸ßÓªÑøÒºÌå»òÆÏÌÑÌǼÓÖ¬·¾È飩һÁ¬µÎ×¢¡£
Tsukamato-French´óÊóÄ£×Ó£º1984Ä꣬TsukamatoFrenchµÈ¸ø´óÊóÊÖÊõÖ²Èëθ¹Ü£¬Ò»Á¬×¢È뺬ÒÒ´¼µÄÒºÌåʳÁÏά³Ö´óÊóѪÖÐ200~300mg/dlµÄÒÒ´¼Å¨¶È£¬ÔìÄ£3¸öÔ£¬»òͬʱÒÔÈÈÁ¿Àο¿£¬º¬ÉÙÁ¿ÓñÃ×ÓÍ(4.9£¥ÈÈÁ¿£©ÒºÌåʳÁÏÒ»Á¬Î¸¹ÜËÇÑø30Ìì¡£
ÒÒ´¼¹àθģ×Ó£ºÔÚÎ¹Ñø¹ÌÌåËÇÁϵÄͬʱÖðÈÕÒÒ´¼¹àθ(11~12g/kg)´óÊó4ÖÜ£¬Ò²¿Éµ¼ÖÂÓëTsukamato-FrenchÒªÁìÏàËÆµÄ¸Î×é֯ѧ²¡±ä¡£Óø߶Ȱ׾Æ(6¡æ×óÓÒ£©ÖðÈÕ¹àθһ´Î(5ml/100g)£¬¸øÓèÓªÑøÈ±·¦ËÇÁÏ£¨Ãæ·Û¡¢´Î·Û¡¢²Ý·Û¡¢¶¹·Û£¬°´2 : 1 : 1 : 1 ±ÈÀýÅä·½£¬Áí¼ÓÉÙÁ¿¶¹Óͼ°Ê³ÑΣ©£¬ÓÚÿÍí½ûʳÖÁÔ½ÈÕÉÏÎç¿Õ¸¹¹àθºóÔÙιËÇÁÏ£¬Ò»Á¬75Ìì¼´¿É±¬·¢¾Æ¾«ÐÔÖ¬·¾¸Î¡£¹àθÒà¿ÉʹÓð׾ơ¢ÓñÃ×ÓÍ¡¢ßÁßò»ìÏýÒº£¨°×¾Æ8~12g/kg£¬ÓñÃ×2g/kg£¬ßÁßò24mg/kg), Ôìģʱ¼äΪ12ÖÜ¡£
¡¾Ä£×ÓÌØµã¡¿£º
MCDÄ£×Ó£ºÇáÓ¯Ò×ÐУ¬µ«·¢²¡¼°ÆäˮƽÓëÊóµÄÐÔ±ð¡¢Æ·Ïµ¡¢ÖÖÀàÓйأ¬ËÇÑøÐ¡Êó1~2Öܼ´ÓÐÏÔ×ŵĸÎÖ¬·¾±ä£¬2Öܺ󱬷¢¸ÎÔ໵ËÀÐÔÑ×Ö¢¼Ì¶ø·ºÆðñ¼ÖܺÍÖÐÑë¾²ÂöÖÜΧÏËά»¯£¬°éѪÇåת°±Ã¸ÏÔÖøÉý¸ßºÍ¸ÎÔàÄÚÖ¬ÖÊÑõ»¯Ã¸»ùÒò±í´ïÉϵ÷£»ÒûʳËÇÑøSprague Dawley´óÊóÔòÏ£ÍûÂý£¬ÔÚÔìÄ£2ÖÜ·ºÆð¸ÎÖ¬·¾±äºÍÑõ»¯Ó¦¼¤£¬5ÖÜʱ·ºÆð¸ÎÔàÑ×Ö¢»µËÀ°éת°±Ã¸Çá¶ÈÉý¸ß£¬12ÖÜ·ºÆð¸ÎÏËά»¯¡£MCDÒûʳιËÇÊó¼¡ÈâºÍÇûÌåÖ¬·¾º¬Á¿ïÔ̰éÌåÖØÏ½µ£¬ÔìÄ£4ÖܺóÍâÖÜ×éÖ¯¶ÔÒȵºËØÃô¸Ð¿É·ºÆðµÍѪÌÇ¡£
HFDÄ£×Ó£ºÔìÄ£4ÖÜ·ºÆðÉ¢ÔÚÐÔ¸ÎÖ¬·¾±ä£¬8ÖÜ·ºÆð´¿´âÐÔÖ¬·¾¸Î£¬12ÖÜΪ֬·¾ÐÔ¸ÎÑ×£¬16ÖܸÎÔàÑ×Ö¢»µËÀˮƽ¼Ó¾ç°éñ¼ÖÜÏËά»¯£¬24ÖÜÖ¬·¾±äºÍÑ×Ö¢ÂÔ¼õÇᣬµ«ÏËά»¯¼Ó¾ç£¬ÉõÖÁ·ºÆð¾àÀëÏËά»¯¡£´óÊ󸹲¿ÄÚÔàÖ¬·¾Ôö¶à£¬ÍâÖÜѪÓÎÀëÖ¬·¾ËáºÍ×ܵ¨¹Ì´¼¾ÙÐÐÐÔÉý¸ß£¬°éÞ²ÂöÄÚ¶¾ËØÑªÖ¢¡¢¸Îϸ°ûÏßÁ£ÌåËðÉË¡¢ÑõÓ¦¼¤Ö¬ÖʹýÑõ»¯ËðÉËÒÔ¼°¸ÎÔà¿â ÆÕ¸¥Ï¸°û¼¤»îµÈÕ÷Ï󣬲¢ÇÒÓÐÒȵºËضԿ¹£¬µ«ÌåÖØºÍѪҺTGÔöÌí²»ÏÔ×Å£¬
TPNÄ£×Ó£ºµ±ÓªÑøÒºÖзÇÂѰ×ÄÜÁ¿Õ¼33£¥ÒÔÉÏ»ò×ÜÉãÈëÁ¿Õ¼×ÜÈÈÁ¿µÄ83£¥ÒÔÉÏʱ£¬1Öܺó´óÊó¸ÎÔ༴ÓÐÏÔ×ŵÄÖ¬·¾±äÐÔ¡£ÈôʹÓÃ¸ßÆÏÌÑÌǺͰ±»ùËáµÄ¸ßÓªÑøÒºÌåÔöÌíÖÁËùÐè·ÇÂѰ×ÖÊÄÜÁ¿µÄ146%£ÛÏ൱ÓÚ350·ÇÂѰ×ÖÊ¿¨/(kg·d)£ÝºÍ335% µªÐèÒªÁ¿£ÛÏ൱ÓÚ2.7g°±»ùËᵪ/(kg·d) ],1/2Ìì¼´·ºÆð¸Î´ó£¬2Ììºó¸ÎÌÇÔ¡¢Ö¬·¾Ôö¶à¡£ÖÁµÚ4Ìì¸ÎÔàÖ¬·¾ÔöÌí4±¶£¬Åãͬ¸ÎÄÚ±ØÐèÖ¬·¾Ëáȱ·¦Öð½¥¼ÓÖØ¡£
ÒÒ´¼¹àθģ×Ó£º¶¯ÎïÌåÖØÔöÌí»ºÂý£¬ÒûʳÁ¿ÏÔ×ÅϽµ£¬´ó²¿·Ö¶¯Îï»á·ºÆð´ó±ãäçй¡£²¡Àí×é֯ѧ¿É¼û¸Îϸ°ûË®Ö×£¬³ÊÆøÇòÑù±ä£¬°ûÖÊÄÚÆÕ±é·ºÆð¾Þϸ²»µÈµÄÔ²ÐÎÖ¬·¾µÎ£¬²¢¿É¼ûÊÈËáÐÔ¹æÔò»ò²»¹æÔòСÌåÐγɣ¬¼´ÒÒ´¼ÐÔ²£Á§Ð¡Ìå¡£»ã¹ÜÇøÑ×֢ϸ°û½þÈóÏÔ×Å£¬²¢¿É¼û½ºÔÏËάÔöÉú£¬¸Îñ¼ÄÚÆ¤Ï¸°ûÖ×ÕÍ¡£
²Î¿¼ÎÄÏ×£º
1.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000
2.Farrell GC, van Rooyen D. Liver cholesterol: is ii playing possum in NASH? Am J Physiol Gastroinlesl Liver Physiol,2012,303 (1):G9-11
3.Maher JJ. New insights from rodent models of fatly liver disease. Anliox.id Redox Signal, 2011, 15 (2):535-550
4.Matsuzawa N,Takamura T, Kurita S, el al. Lipid-induced oxidative stress causes sleatohepalitis in, mice fed an atherogenic diet. Hepatology, 2007,46 (5):1392-1403
5.Sahai A, Malladi P, Pan X, el al. Obese and diabeti db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepalitis: role of sbortform leptin receptors and osteopontin. Am J Physiol Gastroinlest Liver Pbysiol, 2004,287 (5):Gl035-1043
6.Uno M, Kurita S, Misu H,et al. Tranilast,an anlifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepalitis. Hepatology, 2008, 48 (1) : 109-118
7.Xu Z,Chen L,Leung L,el al. Liver-specific i.naclivalion of the Nrfl gene in adult mouse leads lo nonalcoholic steatobepatilis and hepatic neoplasia. Proc Natl Acad Sci US A, 2005, 15; 102 (11):4120-4125